2023-11-08-莱坊-Life_Sciences_Innovation_Insight_Q3_2023_9页_823kb

报告摘要

Pharma and biotech stocks boosted the UK equity market, with the FTSE All Share price rising after a dip, reflecting strong company performance.
Venture capital (VC) funding decreased quarter-on-quarter after a record Q2, but remained robust year-to-date (YTD) at approximately £883 million in Q3, totaling £2.7 billion by the end of the year.
Key sub-sectors outperformed: Pharmaceuticals and biotechnology were added to the FTSE 100 index, with VC backing supporting the upgrade.

Startup activity surged, with 277 new life sciences companies incorporated in Q3, a 9% increase from Q2 and a 31% jump year-on-year.
Cumulatively since the start of the year, 813 life sciences companies have launched in the UK, exceeding the previous high for the first three quarters.

Job openings cooled slightly quarter-on-quarter, with a 3% drop in vacancies for scientific and QA roles.
Open positions remain concentrated in the Golden Triangle (London, Cambridge/Oxford areas), while other regions like the North West, Yorkshire, and Scotland also saw significant activity.

Leasing market: Deals in Q3 included lab-enabled spaces, with high demand in London and Cambridge, priced at £53-£80 per square foot.
Investment market: Total YTD investment in the Golden Triangle reached £568.27 million, with key transactions in properties like The IQ, Cambridge.
Other real estate: Partnerships formed (e.g., Pioneer Group with King's College London) and acquisitions (e.g., Feldberg Capital's acquisition of Brunswick Property Partners) to expand innovation-focused developments.

Key announcements: UK rejoined Horizon Europe, unlocking access to multilateral research funding.
Mansion House Reforms: Aim to redirect pension funds toward growth sectors, potentially freeing £50 billion by 2030.
Investment Zones: Liverpool named England's second zone, targeting life sciences growth; proposals for Cambridge2040 aim to build infrastructure for sustainable expansion.
Funding: Agreements with BioNTech for cancer immunotherapies; establishment of new MHRA approval bodies; ARIA funding for high-risk AI/R&D projects.

M&A activity increased, with large deals like Abcam's acquisition by Danaher (£4.5 billion) and EMIS Group by UnitedHealth Group (£1.24 billion), driven by patent cliff concerns.
AI integration accelerates: Demand for generative AI roles in pharma surged 407%; traditional companies collaborate with AI startups (e.g., Merck and BenevolentAI).
Research growth: UK saw increases in commercial studies, AI-related projects, and NHS collaborations; Cambridge leads in global innovation metrics.

The sector experienced strong fiscal performance despite subtle Q-o-Q declines, with real estate and government support bolstering growth.
Challenges include employment trends and the need for sustained innovation funding.

展开完整摘要